Assaying susceptibility of avian and other influenza A viruses to zanamivir: comparison of fluorescent and chemiluminescent neuraminidase assays - PubMed (original) (raw)
Assaying susceptibility of avian and other influenza A viruses to zanamivir: comparison of fluorescent and chemiluminescent neuraminidase assays
B A Mungall et al. Avian Dis. 2003.
Abstract
Zanamivir has been shown to inhibit both human and avian influenza viral neuraminidases (NAs) and has been approved in several countries for the treatment and prophylaxis of influenza infection. Reliable monitoring of drug resistance is important for assessment of the impact of drug therapy on circulating virus populations. This study compares the current fluorometric (FL) method for evaluating zanamivir susceptibility with a recently developed chemiluminescent (CL) NA activity assay using viruses representative of all nine NA subtypes. The CL assay displayed signal/noise ratios that are 50-100 times greater than those associated with the FL assay. Human H3N2 strains appeared to exhibit greater NA activity relative to avian subtypes with the FL substrate but not with the CL substrate. Additionally, the CL assay remained linear over three orders of magnitude compared to only one order of magnitude for the FL assay. Four of the nine NA subtypes tested in this study displayed slightly higher inhibitor concentration that inhibits 50% of neuraminidase activity values by CL than by FL, while four displayed the opposite effect. Implications for the routine determination of resistance to NA inhibitors are discussed.
Similar articles
- Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir.
Buxton RC, Edwards B, Juo RR, Voyta JC, Tisdale M, Bethell RC. Buxton RC, et al. Anal Biochem. 2000 May 1;280(2):291-300. doi: 10.1006/abio.2000.4517. Anal Biochem. 2000. PMID: 10790313 - Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons.
Mungall BA, Xu X, Klimov A. Mungall BA, et al. Virus Res. 2004 Jul;103(1-2):195-7. doi: 10.1016/j.virusres.2004.02.033. Virus Res. 2004. PMID: 15163509 - Changes in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host.
Thompson CI, Barclay WS, Zambon MC. Thompson CI, et al. J Antimicrob Chemother. 2004 May;53(5):759-65. doi: 10.1093/jac/dkh155. Epub 2004 Mar 17. J Antimicrob Chemother. 2004. PMID: 15028666 - Zanamivir. A potent and selective inhibitor of influenza A and B viruses.
Aoki FY, Hayden FG. Aoki FY, et al. Clin Pharmacokinet. 1999;36 Suppl 1:v-ix. Clin Pharmacokinet. 1999. PMID: 10429834 Review. No abstract available. - Zanamivir: from drug design to the clinic.
Elliott M. Elliott M. Philos Trans R Soc Lond B Biol Sci. 2001 Dec 29;356(1416):1885-93. doi: 10.1098/rstb.2001.1021. Philos Trans R Soc Lond B Biol Sci. 2001. PMID: 11779388 Free PMC article. Review.
Cited by
- Five Novel Non-Sialic Acid-Like Scaffolds Inhibit In Vitro H1N1 and H5N2 Neuraminidase Activity of Influenza a Virus.
Márquez-Domínguez L, Reyes-Leyva J, Herrera-Camacho I, Santos-López G, Scior T. Márquez-Domínguez L, et al. Molecules. 2020 Sep 16;25(18):4248. doi: 10.3390/molecules25184248. Molecules. 2020. PMID: 32947893 Free PMC article. - Reverse-transcription polymerase chain reaction/pyrosequencing to characterize neuraminidase H275 residue of influenza A 2009 H1N1 virus for rapid and specific detection of the viral oseltamivir resistance marker in a clinical laboratory.
Bao JR, Huard TK, Piscitelli AE, Tummala PR, Aleemi VE, Coon SL, Master RN, Lewinski MA, Clark RB. Bao JR, et al. Diagn Microbiol Infect Dis. 2011 Dec;71(4):396-402. doi: 10.1016/j.diagmicrobio.2011.09.003. Epub 2011 Oct 14. Diagn Microbiol Infect Dis. 2011. PMID: 22000086 Free PMC article. - Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective.
Okomo-Adhiambo M, Sleeman K, Ballenger K, Nguyen HT, Mishin VP, Sheu TG, Smagala J, Li Y, Klimov AI, Gubareva LV. Okomo-Adhiambo M, et al. Viruses. 2010 Oct;2(10):2269-2289. doi: 10.3390/v2102269. Epub 2010 Oct 13. Viruses. 2010. PMID: 21994620 Free PMC article. - Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.
Okomo-Adhiambo M, Demmler-Harrison GJ, Deyde VM, Sheu TG, Xu X, Klimov AI, Gubareva LV. Okomo-Adhiambo M, et al. Antimicrob Agents Chemother. 2010 May;54(5):1834-41. doi: 10.1128/AAC.01608-09. Epub 2010 Mar 1. Antimicrob Agents Chemother. 2010. PMID: 20194700 Free PMC article. - Detection of molecular markers of antiviral resistance in influenza A (H5N1) viruses using a pyrosequencing method.
Deyde VM, Nguyen T, Bright RA, Balish A, Shu B, Lindstrom S, Klimov AI, Gubareva LV. Deyde VM, et al. Antimicrob Agents Chemother. 2009 Mar;53(3):1039-47. doi: 10.1128/AAC.01446-08. Epub 2009 Jan 5. Antimicrob Agents Chemother. 2009. PMID: 19124660 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources